The day's most important news and information. A Fourth Estate® Service

Monday, April 19, 2021

Russian Pharmaceutical Company Seeks to Produce Remdesivir Without Patent

Russian pharmaceutical company Pharmasyntez formally asked the Kremlin on Monday afternoon to allow it to produce a generic version of the American COVID-19 drug Remdesivir, despite a lacking a patent to do so.

Russian pharmaceutical company Pharmasyntez formally asked the Kremlin on Monday afternoon to allow it to produce a generic version of the American COVID-19 drug Remdesivir, despite a lacking a patent to do so.

Pharmasyntez director Viram Punia said that the Remdesivir is not available in Russia right now, pointing out that a generic version could be produced and distributed without the consent of the patent-holder Gilead Sciences. 

Puniasaid that the Russian company wrote to the American company in July requesting it consent in the form of a voluntary license, but didn’t hear back.

Pharmasyntez is now asking the government of President Vladimir Putin to officially activate a compulsory licensing process on the basis of national security, granting it the right to produce the generic version of the Remdesivir without the consent of Gilead Sciences. The generic version will be labeled Remdeform.

“Many people’s lives could be saved using this drug. The longer this drug is inaccessible, the more people we will lose,” Punia said.

Article © 2021 Fourth Estate® — All rights reserved.
This material may not be published, broadcast, rewritten or redistributed.

Recent Articles

spot_img

Get the Daily NewsBrief in your inbox

Related Stories